Welcome to our dedicated page for Protalix Biother news (Ticker: PLX), a resource for investors and traders seeking the latest updates and insights on Protalix Biother stock.
Protalix BioTherapeutics, Inc. develops, manufactures and commercializes recombinant therapeutic proteins for rare diseases using its proprietary plant cell-based expression system, ProCellEx®. The company’s recurring news includes financial results, business updates, regulatory developments for Elfabrio® in Fabry disease, and commercial or partnership activity tied to approved enzyme replacement therapies.
Company updates also cover pipeline programs such as PRX-115, a recombinant PEGylated uricase candidate for uncontrolled gout, and PRX-119, a long-acting DNase I program associated with rare kidney disease research. Protalix also reports on collaborations involving RNA-based therapeutic discovery and on its licensed relationship with Pfizer for taliglucerase alfa, Elelyso®, for Gaucher disease outside Protalix-retained rights in Brazil.
Protalix BioTherapeutics (NYSE American: PLX) reported Q1 2026 results and reaffirmed 2026 revenue guidance of $78–$83 million, including a $25 million Elfabrio milestone from Chiesi.
Q1 2026 revenue included $7.4 million from product sales and $26.3 million from license/R&D, driving net income of $18.3 million. Cash and deposits were $51.1 million with no debt. Elfabrio’s EU E4W dosing is approved, and the PRX‑115 Phase 2 RELEASE trial continues, with top‑line data expected in H2 2027.
Protalix BioTherapeutics (NYSE American: PLX) will release first quarter 2026 financial results and provide a business update on May 13, 2026. Management will host a conference call and live webcast at 8:00 a.m. EDT, with replay available for two weeks on the company investor website.
Investors should register 15 minutes early; call and webcast access details and Conference ID 13760475 are provided.
Protalix (NYSE:PLX) reported fiscal 2025 results and business updates on March 18, 2026. Key developments include EC approval of a 2mg/kg every‑4‑weeks (E4W) Elfabrio dosing regimen for adults with Fabry disease, triggering a $25.0 million milestone from Chiesi and supporting an expected $50.0 million cash balance by April 2026.
Management expects 2026 revenue of $78.0–$83.0 million (including the milestone), announced active enrollment in the Phase 2 PRX‑115 gout trial, and highlighted focus on rare renal programs and partnerships.
Protalix BioTherapeutics (NYSE American: PLX) will release its fiscal year 2025 financial results and provide a business update on March 18, 2026. Management will host a conference call and live webcast at 8:00 a.m. EDT to discuss results and recent corporate and regulatory developments.
Call-in numbers, webcast links, conference ID, and replay availability for two weeks on the company's investor events page are provided for investors and analysts.
Protalix (NYSE: PLX) provided a stockholder update outlining 2026 priorities: commercial execution through partners, advancement of PRX-115 for uncontrolled gout, and a focused renal pipeline including PRX-119 and an RNA collaboration with Secarna.
Key facts: Phase 1 PRX-115 showed rapid, durable urate lowering to 6 mg/dL with effects lasting up to at higher doses and generally mild tolerability; an IND for Phase 2 became effective and sites are activated. Commercially, Elfabrio launch metrics track to plan via Chiesi and Elelyso sales continue via Pfizer and Fiocruz. A CHMP negative opinion on a 2 mg/kg E4W Elfabrio regimen is under appeal with an outcome expected in Q1 2026.
Protalix (NYSE American: PLX) and Secarna Pharmaceuticals announced a collaboration and option agreement to discover antisense oligonucleotide (ASO) therapies targeting multiple rare renal indications.
Protalix selected biological targets and Secarna will use its OligoCreator® AI platform to design and profile ASO candidates, with the partners aiming to advance programs from preclinical stages toward clinical trials. Secarna grants Protalix an exclusive option for a worldwide, milestone- and royalty-bearing license to develop, market, and commercialize any active compounds from the research.
Protalix BioTherapeutics (NYSE: PLX) reported third-quarter 2025 results and a business update on November 13, 2025. YTD revenue was $43.6 million, up 24% year-over-year; Q3 revenue was $17.9 million, down 1% year-over-year. Q3 net income was ~$2.4 million ($0.03/share); YTD net loss was ~$1.1 million ($0.01/share).
R&D spending rose substantially as the company prepares a phase 2 trial of PRX-115; the company submitted an IND in October 2025 that became effective after the FDA 30-day review. A CHMP negative opinion on an Elfabrio dosing variation led to a re-examination request by Chiesi; the approved 1 mg/kg E2W Elfabrio regimen remains unchanged. Cash and equivalents were $29.4 million, stated sufficient for at least 12 months from the quarterly report date.
Protalix BioTherapeutics (NYSE American: PLX) will release its financial results for the quarter ended September 30, 2025 and provide a business update on November 13, 2025.
Management will host a conference call at 8:00 a.m. Eastern Standard Time with toll-free and international dial-ins and a live webcast. Participants are asked to join 15 minutes early to register and install any required audio software. A replay will be available for two weeks on the company's Investors Events Calendar.
Protalix BioTherapeutics (NYSE American:PLX), a biopharmaceutical company specializing in recombinant therapeutic proteins using its ProCellEx® plant cell-based protein expression system, has announced its participation in the upcoming Q3 Investor Summit Virtual.
The company's former Senior Vice President and CFO, Eyal Rubin, will deliver a presentation on September 16, 2025, at 10:30 AM EDT. The presentation will focus on the company's growth strategies and market opportunities, and will be accessible via webcast.
Protalix BioTherapeutics (NYSE American:PLX), a biopharmaceutical company specializing in plant cell-based protein expression systems, has announced its participation in the H.C. Wainwright 27th Annual Global Investment Conference.
CEO Dror Bashan will deliver a presentation on Monday, September 8, 2025, at 3:30 PM EDT in the Holmes II Room at the Lotte New York Palace Hotel. The management team will also engage in one-on-one meetings with registered investors throughout the conference.